Neurocrine Biosciences, Inc’s recently made public that its Officer INGRID DELAET acquired Company’s shares for reported $94584.0 on Feb 03 ’25. In the deal valued at $151.82 per share,623 shares were bought.
Then, JULIE COOKE bought 824 shares, generating $126,311 in total proceeds.
Before that, KEVIN CHARLES GORMAN bought 2,707 shares. Neurocrine Biosciences, Inc shares valued at $414,956 were divested by the Director at a price of $153.29 per share.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “an Overweight”. Wells Fargo also remained covering NBIX and has increased its forecast on April 24, 2024 with a “an Overweight” recommendation from previously “an Equal weight” rating.
Price Performance Review of NBIX
On Monday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock fall -1.13% to $150.10. Over the last five days, the stock has gained 1.29%. Neurocrine Biosciences, Inc shares have risen nearly 9.96% since the year began. Nevertheless, the stocks have risen 7.39% over the past one year. While a 52-week high of $157.98 was reached on 01/30/25, a 52-week low of $110.95 was recorded on 01/06/25. SMA at 50 days reached $136.20, while 200 days put it at $133.59.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 148.20, which if violated will result in even more drops to 146.31. On the upside, there is a resistance level at 151.81. A further resistance level may holdings at 153.53. The Relative Strength Index (RSI) on the 14-day chart is 66.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.52, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 28.27%. Stochastics %K at 82.25% indicates the stock is a selling.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-01-15, dropping by -0.19 million shares to a total of 3.2 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 3.39 million shares. There was a decline of -5.9%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $136 price target.
